Results 221 to 230 of about 55,676 (335)

Intramolecular regulation of Janus kinases

, 2017
Janus-kinaasit (JAKit) ovat ei-reseptorisia tyrosiinikinaaseja, jotka välittävät yli 60 sytokiinin viestejä soluissa. Nämä viestit säätelevät lukuisia biologisia tapahtumia, kuten immuunijärjestelmän toimintaa, hematopoieesia, aineenvaihduntaa sekä kehitystä.
openaire   +2 more sources

Janus-family tyrosine kinase

Citation: 'Janus-family tyrosine kinase' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13352 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual ...
openaire   +1 more source

Treatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims‐Based Study

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co‐occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern.
Masaki Futamura, Yumi Kang, Ambrish Singh, Junichi Danjo, Takashi Matsuo, Hitoe Torisu‐Itakura, Mizuho Nagao   +6 more
wiley   +1 more source

POS0479 Steroid-sparing effect of Janus kinase inhibitors compared to TNF inhibitors in rheumatoid arthritis: preliminary analysis from a single-center Italian cohort

Gilberto Cincinelli, V. Gerli, D. Pireddu, Giorgia Trignani, Francesco Ursini, A. Varvaro, Ennio Giulio Favalli, Roberto Caporali   +7 more
openalex   +1 more source

Janus kinase (JAK) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

Correction to "Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution". [PDF]

Pharmacol Rev, 2020
europepmc   +1 more source

Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study [PDF]

, 2018
Elena Peeva, Martin R. Hodge, Elizabeth Kieras, Michael L. Vazquez, Kosalaram Goteti, Sanela Tarabar, Christine Alvey, Christopher Banfield   +7 more
openalex   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases. [PDF]

Sci Rep, 2018
Hammitzsch A, Chen L, de Wit J, Al-Mossawi MH, Ridley A, Sekine T, Simone D, Doig K, Skapenko A, Bowness P.   +9 more
europepmc   +1 more source